Congress targets infant formula deception—but protects families' right to sue

What it does

This bill directs the Federal Trade Commission to investigate whether manufacturers of preterm infant formula are using unfair or deceptive advertising—specifically, whether they are hiding information about health risks or downplaying the benefits of human milk-based fortifiers compared to bovine (cow's milk) fortifiers. Based on the investigation, the FTC must issue regulations within 18 months prohibiting such deceptive practices. The bill is motivated by concerns about necrotizing enterocolitis (NEC), a serious intestinal disease that kills one preterm infant per day, and aims to ensure parents have full information to protect their infants' health and preserve their right to sue if harm occurs.

Why we flagged it

The bill's operative mechanism is a consumer-protection investigation and rulemaking by the FTC to prevent deceptive marketing of a medical product for vulnerable infants. It is not a subsidy, carve-out, or immunity grant—it is a regulatory enforcement tool aimed at transparency and accountability.

What the text implies

• The bill's 'Sense of Congress' section (Section 2) explicitly states that 'no manufacturer of preterm infant formula or related products should be permitted to limit, evade, or otherwise diminish the ability of families to pursue legal recourse.' This language may be interpreted as a directive to the FTC to scrutinize or prohibit arbitration clauses, liability waivers, and class-action bans in pro
• The bill requires the FTC to consider 'differences, including with respect to benefits and drawbacks, between consuming human breast milk and human milk-based fortifiers and consuming bovine-based fortifiers.' This directive may obligate manufacturers to affirmatively disclose comparative safety data, shifting the burden of proof and potentially requiring disclosure of unpublished or proprietary r
• The exemption from the Paperwork Reduction Act (Section 3(1)(3)) removes a procedural check on the FTC's investigative authority, allowing the agency to demand information from manufacturers without the usual notice-and-comment period for information collection. This accelerates the investigation but reduces transparency in the FTC's own process.
• The bill's focus on 'preterm infant formula' (defined as formula exempt under FDA Section 412(1)) is a narrow product category. Manufacturers of standard infant formula are not directly regulated, creating a potential competitive advantage for non-preterm formulas and possibly incentivizing market segmentation or relabeling to avoid the new rules.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill empowers the FTC to police deceptive marketing of a product that directly affects vulnerable infants' health and survival. It mandates transparency about health risks and comparative benefits, giving parents the information they need to make informed decisions. The bill also explicitly protects families' right to legal recourse—a core accountability mechanism—by prohibiting manufacturers from using liability shields or arbitration clauses to block lawsuits when infants are harmed.

Who stands to gain

• Manufacturers of human milk-based fortifiers
• Plaintiffs' personal-injury law firms (expanded litigation opportunity)
• Hospitals and NICUs (potential liability reduction if safer products are adopted)

Named in the bill

Federal Trade Commission (FTC), Preterm infant formula manufacturers, Bovine fortifier manufacturers, Human milk-based fortifier manufacturers, Nestlé (ON — mapped stock), Danone (BE — mapped stock), FDA, Congress

Where it stands

2 cosponsors: 2 Democrats.

• Jul 27, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 27, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.